VigiLanz and Cincinnati Children’s Collaborate to Commercialize a Real-Time Solution to Minimize Acute Kidney Injury in Pediatrics

MINNEAPOLIS & CINCINNATI – (November 29, 2018) – VigiLanz and Cincinnati Children’s Hospital Medical Center today announced a collaboration that leverages Cincinnati Children’s ground-breaking research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for Acute Kidney Injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

“Pediatric acute kidney injury is a serious problem that traditionally could not be identified in real-time, which impacted our ability to identify the patients who most needed treatment,” stated Dr. Stuart L. Goldstein, MD, FAAP, FNKF, Director of the Center for Acute Care Nephrology and primary researcher on NINJA.  “By partnering with VigiLanz, Cincinnati Children’s is applying our unprecedented research to a commercially-available solution that accurately characterizes pediatric AKI epidemiology, reducing AKI and improving patient outcomes.”

Commercially available to hospitals and health systems focused on mitigating pediatric AKI, NINJA automates a time-consuming manual screening process that includes evaluating patients for exposure to 57 nephrotoxic medications, imaging contrast dye, and recent renal testing. For medications, manual screening is limited to the last 24 hours, while the contrast dye evaluation requires reviewing records for the previous seven days to determine if it was received by the patient.

Leveraging NINJA algorithms built into VigiLanz rules, an AKI monitoring dashboard lists all patients that meet the NINJA exposure criteria as well as the criteria that put the patient in the at-risk category. These criteria include medication exposure, serum creatinine data, and patient history of AKI. When patients meet at-risk criteria, they are placed on the monitoring list in real time, where they remain until 48 hours after their risk has passed.

The platform also features metric outputs that can be customized with respect to service lines and time periods, while robust reporting tools provide the ability to trend conditions over time via automated run charts. It also enables automatic and customizable data extraction for all metric elements, including inpatient census by location or service line.

“By expanding awareness of the extensive research conducted by Cincinnati Children’s, this partnership will help drive improvements in pediatric AKI outcomes,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Those improvements can be realized quickly, too, as the NINJA dashboard is not just a concept but rather a tangible solution now available to any hospital interested in limiting AKI associated with nephrotoxic drugs.”

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

Interoperability in Real Life: Practical Ways to Leverage APIs & Transform Healthcare

Interoperability between EMRs and other applications is a key challenge in healthcare today. Application Programming Interfaces (APIs) have transformed interoperability in other industries and now healthcare, too, is increasingly relying on them to solve important clinical and business problems. VigiLanz recently co-hosted a panel discussion on the topic, with one of its partners, Sansoro Health, which featured leaders from a diverse group of healthcare organizations, who shared how they use proven API solutions to successfully address complex, real-world clinical, operational and workflow challenges.

Although the three panelists were at different stages of their journey in leveraging APIs to provide better healthcare solutions, more rapidly and at lower cost, all recognize that legacy technology does not meet their needs for integration with EMRs and data liquidity.

The Longest-Established API User

As moderator of the panel discussion, David Levin, MD, Chief Medical Officer of Sansoro Health and former CMIO of Cleveland Clinic Health System, explained it’s vital to have bi-directional data flow back into EMRs to save clinicians from double documenting. It’s an issue that Peter Chang, MD, Chief Medical Information Officer, Tampa General Hospital, faced, until he implemented Sansoro Health’s Emissary® API solution to deliver efficient, real-time read-and-write EMR interaction across complete patient demographics and clinical data. The longest established API user of the group, Dr. Chang spoke about how his hospital leverages APIs to focus solely on their application and not get disrupted on the integration. Tampa General Hospital can now integrate in a matter of days across EMRs, sourcing all the data its clinicians need.

The Middle Stage of the Middleware Journey

Adam Klass, Chief Technology Officer of VigiLanz, at the middle stage of the middleware journey, spoke on how APIs reduce barriers to EMR integration and can be rapidly deployed to provide robust, real-time interoperability between complex applications. To help healthcare providers deliver real-time results and  improve interoperability, he described how medical facilities today require a services-oriented architecture and API. The API must enable efficient aggregation, interaction and exchange of disparate data throughout the health care enterprise and across any of its software technologies, including EMRs and third-party vendors.

Klass, one of the company’s original founders in 2001, outlined the company’s mission of providing real-time clinical decision support to its customers by helping with all manners of manual data collection processes, using data and real-time rules engines. From pharmacy surveillance and predictive models to antimicrobial stewardship and other clinical use cases, the company relies on receiving EMR data in a timely manner. VigiLanz has always sought to answer the question of how to extract data from an EMR. It wasn’t rocket science, in Klass’ words, and yet it was challenging to collect the same data from every hospital in every EMR, in a way that enabled customers to have an intimate understanding of provider behavior through benchmarking. A creative solution was needed.

It’s one reason VigiLanz partnered with Sansoro Health to develop its VigiLanz Connect solution, which plugs into an organization’s EMR in less than one week for hospital IT-lite integration. Traditional integration methods are often customized for each installation, require regular maintenance and cannot be reused. Using a standard set of population-based APIs that facilitate seamless, real-time, bi-directional data flow, VigiLanz Connect normalizes data faster—and empowers clinicians to make an impact sooner. It plugs in once to deliver standardized, interchangeable APIs for seamless integration across all data sources. VigiLanz Connect has now been successfully deployed at several hospitals.

Exploring the Advantages to APIs

Matthew Cunningham, Executive Vice President of eviCore, described how his company is comprised of more than one thousand doctors and nurses in its ranks, so it needs a robust, flexible platform to identify and distribute the precise data and analytics to make informed, individual-based decisions across the 100 million lives it manages. With an understanding for the types of clinical and business problems that can be addressed with API technology, eviCore has begun to explore the advantages of commercially available APIs, like Sansoro Health’s Emissary platform.

Plug-and-play EMR integration is a reality today. Within days, hospital organizations are up and running with a standard set of APIs that work the same across EMRs. By leveraging middleware, organizations only code their application once for seamless integration across all data sources. This eliminates the need to build traditional custom interfaces for each EMR, saving significant time, resources and reducing costs – for clinicians, the hospital IT department and third-party solutions.

Connexall and VigiLanz Combine Antimicrobial Stewardship with Intelligent Routing to Improve Patient Safety

BOULDER, CO & TORONTO, ON – (February 28, 2018) – Connexall and VigiLanz, both named Category Leaders in the 2018 Best in KLAS awards, have teamed up to deliver time-sensitive information related to antimicrobial stewardship (AMS) to increase patient safety and improve outcomes at hospitals.

The VigiLanz AMS platform aggregates information from physician order entries, laboratory and pathology reports, and the EHR to provide continuous surveillance of patients.  Connexall integrates with VigiLanz and the EHR to intelligently route data quickly and reliably to the assigned care team for the affected patient. This guides the care team to ensure safe and appropriate use of antibiotics.

“AMS has emerged as a central component of highly effective care quality and safety strategies, and success requires the ability to rapidly transform data into action,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “This partnership between VigiLanz and Connexall does just that, providing our customers with a robust AMS solution that leverages the power of two KLAS category leaders to drive improved patient outcomes.”

“Connexall is delighted to partner with VigiLanz to enhance antimicrobial stewardship programs for the benefit of patients.” stated David Tavares, GlobeStar/Connexall CEO.  “Our intelligent routing capabilities ensure that the assigned care team is notified promptly and reliably to deliver the care the patients require.” continued Tavares.

To learn more about this progressive solution, please visit VigiLanz at Booth #2674 and Connexall at Booth #8105 at HIMSS18.

About Connexall

Connexall, ranked number one and named Category Leader in the 2015/2016, 2017, and 2018 Best in KLAS awards, is an enterprise-grade event management and control platform that delivers hospital-wide interoperability to people, systems, tasks, and devices.  Its capabilities act as a backbone for clinical workflow, communicating the right information to the right person, at the right time, on the right device. Based on more than 20 years of R&D efforts, the Class II medical device software is completely vendor-neutral and device-independent. Connexall has offices in Canada, the United States, Brazil, Portugal and Hong Kong and works with well over a thousand of the world’s most renowned and progressive hospitals and health systems.  For more information please visit www.connexall.com.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Ranked #1 in Best in KLAS Report for Infection Control and Clinical Decision Support-Surveillance Categories

MINNEAPOLIS – (January 31, 2018) – VigiLanz, a digital healthcare intelligence firm, announced today that it has earned 2018 Category Leader designations for Infection Control and Clinical Decision Support-Surveillance in the 2018 Best in KLAS: Software and Services report. These mark the second and third KLAS honors in the past year for VigiLanz, which also achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report for its platform, customer partnerships, and dedication to customer service and support.

In the “2018 Best in KLAS: Software and Services,” report, released on January 30, VigiLanz’s Dynamic Infection Control Monitor  product garnered a score of 90.3 while its Dynamic PharmacoVigilance product earned an 89.9.

The Category Leader designation is reserved for vendor solutions that lead select market segments in which at least two products meet a minimum level of KLAS Konfidence. Rankings are based on customer surveys of North American hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment solutions.

Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s standard EHR system. Via an automatic exception-based alert system, all patient records are under continuous surveillance to alert decision makers in real time to potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern and reportable infections. The surveillance is based on a sophisticated set of rule engines that can be customized for each hospital.

Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, the system automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“VigiLanz is honored to see our solutions recognized as Category Leaders, particularly as healthcare professionals are the engine that drives KLAS’ impartial research on the software and services used by providers worldwide,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Following upon VigiLanz’ recognition by KLAS in 2017 for our Antimicrobial Stewardship products, these additional designations further validate our reputation among clinicians and administrators alike as a company that offers the best, top-performing solutions in the industry.”

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Unveils Automated Safety Event Detection and Reporting

MINNEAPOLIS – (December 6, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today the launch of a state-of-the-art automation solution that helps hospitals optimize safety event reporting and enhance compliance with accreditation requirements. VigiLanz® Dynamic Safety Surveillance transforms clinical data into actionable intelligence, empowering hospitals to achieve greater risk reduction through automated safety event detection, management and analytics.

Patient falls and adverse drug events are the most common safety events, which also include surgical errors, wrong blood products, injuries to employees and visitors, and workplace violence. As many as 440,000 people die annually from hospital errors, injuries, accidents and infections. To help combat these issues, The Joint Commission made safety event reporting a requirement for accreditation, which uses the information to improve quality and safety of its hospitals.

Despite the importance of safety event reporting, hospitals are confronted with several barriers that prevent a comprehensive accounting of adverse occurrences. These include:

  • Limited information on the event
  • The time required to complete incident forms
  • A lack of urgency to report events considered too minor
  • Confusion over reporting responsibilities

VigiLanz Dynamic Safety Surveillance overcomes these obstacles by automating the common approaches to managing, reporting and detecting safety events—including capturing information on serious unsafe conditions and resulting adverse events that previously went unreported.

“Those unreported incidents have the potential to do significant long-term harm, as even minor events can escalate into serious, even deadly, situations,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Over-reliance on humans to identify and report safety events exposes hospitals to repercussions ranging from loss of payment for ‘never events’ and damaged reputations to patient grievances and lawsuits. VigiLanz Dynamic Safety Surveillance mitigates those risks with a powerful set of monitoring and reporting tools that supplement human actions for comprehensive reporting.”

VigiLanz Dynamic Safety Surveillance integrates clinical data from multiple sources with comprehensive detection and investigation tools, automated escalation, and a full library of analytical and reporting tools into a single solution that:

  • Accelerates the event reporting life cycle through customized workflows
  • Converts health data automatically into uniform intelligence for more complete reporting and event detection
  • Provides comprehensive tools for efficient analysis
  • Generates state of the art dashboards for real-time monitoring

“The business of safety reporting starts with an organizational culture that embraces reporting all safety events,” said Dr. Goldsteen. “VigLanz Dynamic Safety Surveillance takes it to the next level with a tool that facilitates communications about all safety events, including those that might otherwise go unreported.”

For a demonstration of its new Safety Surveillance solution, visit VigiLanz in Booth #212 at the IHI National Forum, taking place Dec. 10-13 in Orlando, Fla.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Integrates Infectious Disease Content from Sanford Guide

MINNEAPOLIS – (November 29, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today that users of its market-leading clinical intelligence platform now have direct access to the industry’s top digital infectious disease content. Integrating content from The Sanford Guide lets clinicians and pharmacists take the critical next step in the antimicrobial de-escalation process by leveraging peer-reviewed recommendations on the latest treatments—without having to exit the VigiLanz workflow.

Through its exclusive partnership with Sanford Guide, the most trusted name in the treatment of infectious disease, VigiLanz clients can access the full suite of digital infection disease content and associate it with specific rules. Users can then search comprehensive coverage of the latest clinician-designed treatment options for infectious diseases, syndromes, and pathogens from within the VigiLanz system, driving improved patient outcomes.

“The value of this partnership to our clients extends beyond their VigiLanz users to include any clinician or pharmacist in need of the actionable treatment recommendations, tailored for use in clinical scenarios, from anywhere across the enterprise,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA.

Noting that the company’s antimicrobial stewardship platform recently achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report from KLAS Research, Goldsteen added, “The Sanford Guide’s exceptional content and clinical guidance are the perfect complement to our nationally-recognized platform, advancing care quality and patient safety through industry-leading guidance on the treatment of infectious diseases.”

The VigiLanz clinical intelligence platform leverages real-time monitoring of thousands of patient care data elements to help improve medication safety, antimicrobial stewardship, infection prevention, quality and care management, and patient safety. Its state-of-the-art rules engine analyzes that data and pushes alerts to clinicians at the point of care when interventions and other actions are necessary, driving significant improvements in safety, efficiency, performance, and reimbursement.

Trusted by clinicians in more than 100 countries, The Sanford Guide is optimized to minimize time-to-answer while providing comprehensive guidance at the point of care. With continually updated information based on the latest available evidence, focused anti-infective drug information, interactive dosing tables, and extensive links to references and related resources, The Sanford Guide provides actionable guidance that is accessible, concise, and reliable.

“By integrating The Sanford Guide’s trusted clinical treatment recommendations with its top-rated clinical surveillance tools, VigiLanz is helping hospital and health systems take their approach to infectious disease and antimicrobial stewardship to the next level,” said Sanford Guide CEO and Managing Editor Jeb Sanford.

For more information on the integrated VigiLanz-Sanford Guide solution, visit VigiLanz in booth #1641 during the ASHP Midyear Clinical Meeting And Exhibition, taking place Dec. 3-7 in Orlando, Fla.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Becomes First Clinical Intelligence Platform to Integrate Sanford Guide Infectious Disease Content

MINNEAPOLIS, MN and SPERRYVILLE, VA. – (September 26, 2017) – VigiLanz, a digital healthcare intelligence firm, and Antimicrobial Therapy Inc., publisher and developer of The Sanford Guide, announced today an exclusive partnership that brings together the market-leading clinical intelligence platform and the industry’s top digital infectious disease content. Doing so provides VigiLanz users with the critical next step in the clinical surveillance process—access to peer-reviewed recommendations on the latest treatments for improved patient outcomes.

The agreement with Sanford Guide, the most trusted name in the treatment of infectious disease, is just the latest in a string of achievements for VigiLanz. Most recently, its antimicrobial stewardship platform achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report from KLAS Research.

The VigiLanz clinical intelligence platform leverages real-time monitoring of thousands of patient care data elements to help improve medication safety, antimicrobial stewardship, infection prevention, quality and care management, and patient safety. Its state-of-the-art rules engine analyzes that data and pushes alerts to clinicians at the point of care when interventions and other actions are necessary, driving significant improvements in safety, efficiency, performance, and reimbursement.

“Integrating Sanford Guide content into this process answers the question, ‘What’s next in the antimicrobial de-escalation process?’ by giving clinicians and pharmacists convenient access to the latest clinician-designed treatment recommendations without having to exit the VigiLanz system,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “We are proud to provide our clients with access to The Sanford Guide’s exceptional content and clinical guidance, more so because we are the first and only clinical intelligence platform able to do so.”

Trusted by clinicians in more than 100 countries, The Sanford Guide is optimized to minimize time-to-answer while providing comprehensive guidance at the point of care. Edited by distinguished infectious disease experts from leading academic and clinical centers, Sanford Guide content provides comprehensive coverage of treatment options for infectious diseases, syndromes, and pathogens. Under the partnership agreement, VigiLanz clients will have access to the full suite of Sanford Guide digital infectious disease content.

With continually updated information based on the latest available evidence, focused anti-infective drug information, interactive dosing tables, and extensive links to references and related resources, The Sanford Guide provides actionable guidance that is accessible, concise, and reliable.

“This partnership with VigiLanz is the most unique collaboration our company has undertaken since its founding nearly 50 years ago. As we moved forward with ever more sophisticated digital offerings, it was imperative that the company we aligned with share our values and commitment to improving the quality of treatment through focused clinical guidance at the point of care. VigiLanz was that company,” said Sanford Guide CEO and Managing Editor Jeb Sanford. “Together we have created a product that fully integrates trusted clinical treatment recommendations with top-rated clinical surveillance tools. Our goal is to improve patient outcomes while minimizing technology burdens on providers.”

For more information on the VigiLanz-Sanford Guide partnership, visit VigiLanz in booth #226 or Sanford Guide in booth #710 during IDWeek 2017, taking place October 4-8 in San Diego, CA.

About Sanford Guide

Since 1969, Sanford Guide has been a leader in point-of-care recommendations for the treatment of infectious diseases. Widely used by pharmacists, physicians, physician assistants, and nurses, Sanford Guide helps to improve patient care by providing carefully curated recommendations based on the latest evidence. With over 1 million users worldwide, Sanford Guide takes pride in responsiveness to customers, the development of innovative solutions, and providing content that is unparalleled in quality and clinical applicability.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Achieves Top Rating for Overall Satisfaction in KLAS AMS Performance Report

MINNEAPOLIS – (Aug. 31, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today that its antimicrobial stewardship platform achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report from KLAS Research. In identifying VigiLanz as the market leader, KLAS cited the platform’s highly robust, fairly user-friendly platform, the strength of the firm’s partnerships with customers, and its dedication to providing the guidance necessary to ensure customizations meet end users’ needs.

“The key is real-time alerting, and Antimicrobial Stewardship has it. The system is able to alert clinicians to certain conditions, even when the physicians are at home having dinner. It is nice to get alerts when we aren’t in front of the EMR,” according to one VigiLanz customer.

To compile its report, KLAS conducted in-depth interviews with current customers of each participating vendor to better understand which antimicrobial stewardship (AMS) tools are helping to drive meaningful interventions and track internal metrics. Interviews also focused on how well users can customize rule sets and use antibiograms to meet organizations’ unique goals, as well as which vendors help customers optimize tools and prepare for future reporting requirements.

Writes KLAS, “Providers new to AMS programs highly value guidance and expertise from their vendors, and VigiLanz’s proactive support has driven their top overall satisfaction rating. Provider interest in VigiLanz has grown over the last few years, and customers receive strong guidance and expertise that ensures their success.”

VigiLanz, which had the highest number of customers interviewed by KLAS, excelled in a large number of the evaluation categories. Under performance indicators, 100% of users said they would buy the platform again and that VigiLanz kept all promises. The platform also exceeded the market average for functionality of its custom rules set and customizable antibiogram. It was also singled out for being farthest along the compliance reporting spectrum, delivering on the three basic fronts of making AMS data accessible within the system for reporting, communicating with customers about forthcoming regulations and actions underway to help them prepare, and automating reporting. Specifically, customers have access to reports that can be submitted directly to the National Healthcare Safety Network (NHSN).

Also noteworthy is that a significant majority of respondents were satisfied or extremely satisfied with the VigiLanz platform’s ability to track key internal metrics and with its optimization services. This is an important distinction because, as KLAS notes, “internal tracking is crucial to a good AMS program because it enables users to see trending and benchmarking data. It can be tricky to do well because data from many different sources must be aggregated, analyzed and made easy to digest. VigiLanz customers have strong customization abilities and highly value VigiLanz’s robust interfaces, which successfully pull in data from many areas.”

“As more healthcare organizations seek to automate the crucial AMS process, it is important to partner with a vendor that can provide a solution that is flexible, robust and backed by outstanding customer support,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “It is truly gratifying to know that our customers feel that VigiLanz is that solution.”

About KLAS

KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider’s voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services and medical equipment to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance. Follow KLAS on Twitter.

VigiLanz Platform Earns Meaningful Use Stage 3 Certification for Antimicrobial Use and Resistance Reporting

MINNEAPOLIS, Minn. – (March 6, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today that its antimicrobial stewardship platform has earned Meaningful Use Stage 3 (MU3) certification validating its ability to collect and properly report data around antimicrobial use and resistance. The company is one of the first to achieve Stage 3 certification for use by facilities enrolled in the National Healthcare Safety Network (NHSN) that are required to begin reporting Antimicrobial Use and Antimicrobial Resistance (AUR) data in 2018.

A new option for public health registry reporting under MU3, collection of AUR data is already underway in preparation for the 2018 reporting period. Participating facilities must submit monthly reports on anti-infective medications—antibiotics, anti-bacterials, antifungals, antivirals, antiprotozoals, etc.—that the Centers for Disease Control and Prevention (CDC) will use to gain a better understanding of how their use impacts antimicrobial resistance in hospitals and healthcare facilities. The AUR objective calls for reporting a full calendar year’s data on R1 Normative Antimicrobial Use Summary, Antimicrobial Resistance Event, and Antimicrobial Resistance Summary data to be reported using Clinical Documentation Architecture (CDA) formatting.

“Inappropriate antibiotic utilization and multidrug resistant organisms are among the deadliest threats confronting the healthcare system today. That is why it was so important to us to achieve MU certification for AUR data collection and reporting,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA, noting that drug resistant organisms alone infect 2 million people and claim 23,000 lives in the U.S. every year, while adding $34 billion to annual healthcare costs. “It lets us play an active role in addressing this dangerous and costly phenomenon.”

Submission of AUR data into the NHSN platform allows clinicians to benchmark their antibiotic usage and organism resistance data nationally to target areas of improvement.

VigiLanz spent six months working on updates to its platform in preparation for its certification application. As such, it can properly collect and report data in the CDA format retroactively to January 1, 2017. Any customer with Dynamic Antimicrobial Stewardship or Dynamic Pharmacy Surveillance modules that is currently sending electronic medication reconciliation data can take advantage of certification without the need for additional upgrades, and without incurring any additional costs. VigiLanz also has the means to assist clients not yet collecting this data, to do so retroactively.

Part of VigiLanz’ clinical intelligence platform, the antimicrobial stewardship solution leverages data collected from a hospital’s electronic medical record, physician order entry, laboratory and pathology systems to monitor patients in real-time for drug interactions and ineffective or inappropriate antibiotics. When potential issues are identified, alerts are triggered to enable clinical pharmacists and other members of the care team to take appropriate action.

Certification Information:

“This Health IT Module is 2015 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services.  This certification does not represent an endorsement by the U.S. Department of Health and Human Services.”

Product(s) Certified:

Dynamic Antimicrobial Stewardship
Dynamic Pharmacy Surveillance
VigiLanz Corporation http://vigilanzcorp.com
5775 Wayzata Boulevard, Suite 970 Minneapolis MN 55416
Contact: Stacy Pur, VP of Clinical Product Management
Phone: (855) 525-9078
Modules Tested: 170.315 (d)(1-3, 7); (f)(6); (g)(4,5)
Clinical Quality Measures tested: None
Additional software used: None
Holds Certificate No: 15.04.04.XXXX.Dyna.17.0.0.170217
Date Certified: 02/17/2017
Effective Date:  2015 Edition

Disclosure Statement:

This certified product-version requires a one-time implementation fee and an annual licensing fee. This certified product-version is certified to data export criteria 170.315(f)(6.) and can generate Antimicrobial Use and Resistance CDA reports in real-time however this monthly data is not available until the 4th of each month to allow time for facility information to finalize.

How Orlando Health Deploys Predictive Analytics to Fight Sepsis

As a result of the prevalence of sepsis in the healthcare setting and new reimbursement models that reward value and outcomes, many health systems and hospitals are looking for ways to take full advantage of all technological resources available in order to protect patients and reduce costs by working to properly manage and prevent sepsis.

While CMS assesses hospital performance by monitoring 30-day readmissions following hospitalizations for heart attack, heart failure, chronic obstructive pulmonary disease and pneumonia, none of these conditions take the same toll on hospitals and their patients in terms of readmissions as sepsis, according to a recent study published in JAMA. In the study, researchers found sepsis — a condition caused by the body’s immune response to life-threatening infection — accounted for 12.2 percent of readmissions, followed by 6.7 percent for heart failure, 5 percent for pneumonia, 4.6 percent for COPD and 1.3 percent for heart attack.

During a Jan. 26 webinar sponsored by VigiLanz — a provider of real time intelligence and predictive analytics — and hosted by Becker’s Hospital Review, Eric Rose, Pharm. D, manager in corporate clinical decision support at Orlando (Fla.) Health, Adam Klass, chief technology officer with VigiLanz, and Bart Abban, PhD, director of analytics and data science with VigiLanz, discussed the development of predictive models for sepsis risk and how such models can improve outcomes by alerting physicians to the early signs of sepsis and enabling them to intervene sooner.

The VigiLanz intelligence platform conducts automated, continuous surveillance to provide clinicians with solutions and insights in real time to ensure adherence to best practices, increase patient safety and improve reimbursement.

“We’re a layer that sits on top of the EMR and really our goal is to drive all of the value out of all of that great data that’s in the EMR and really affect patient care in real time,” said Mr. Klass during the webinar.

The VigiLanz platform is designed to deliver clinicians predictive analytics tailored to a hospital’s patient population. Patient attributes like age, clinical history, comorbidities and lab results can be continuously introduced into the model. The VigiLanz model also analyzes the potential effects of a patient’s unique history and attributes on their clinical outcomes.

Additionally, models are constructed from the ground up through collaboration between the VigiLanz team and the hospital, tested against a hospital’s historical data and validated within a staging environment.

“We have a very collaborative process between your experts and the VigiLanz team,” said Dr. Abban, during the discussion. “Based on the literature available, we’ve built great base models. When we begin working with [a hospital’s] team, we look at the important differences that are in your institution, things that might impinge on the foundational models and we incorporate those into the models.”

The pilot model designed to predict the risk of sepsis in patients at Orlando Health — a six-campus health system with 1,700 beds and a Level I trauma center — involves a multi-layer process. First, efforts are made to accurately identify patients already presenting sepsis upon admission. Second, patient data like vital signs, microbiology and clinical history are entered into the model. Then the platform conducts a clinical evaluation and attributes a sepsis risk score to the patient. Based on the score, hospitals can decide when medical interventions are warranted and more effectively triage the patient population.

At Orlando Health, the VigiLanz model has a positive sepsis predication rate of 70 percent and has been particularly well received in the med-surgery units.

Additionally, Orlando Health’s Dr. Rose and the VigiLanz team were able to establish more accurate time frames for organ dysfunction pertaining to sepsis. According to Dr. Rose, the newly established time frames “helped us very quickly tighten up the predictive power of the algorithm.”

“It’s really been a pleasure to partner with them [VigiLanz] on this new venture in predictive analytics,” said Dr. Rose.

To view the webinar, click here.

Article reposted with permission from Becker’s Healthcare. See the original here.